PubMed ID:
18571276
Public Release Type:
Journal
Publication Year: 2008
Affiliation: Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
DOI:
https://doi.org/10.1016/j.jhep.2008.04.011
Authors:
Hoofnagle JH,
Fontana RJ,
Wang D,
Kleiner DE,
Terrault N,
Seeff LB,
Zacks S,
Afdhal N,
Agudelo E,
Baker SM,
Belle SH,
Bilonick RA,
Block G,
Brown RS Jr,
Brown S,
Burton JR,
Callison K,
Cannon N,
Cline J,
Conjeevaram HS,
Davis P,
DeMedina M,
Di Bisceglie A,
Donlin M,
Doo E,
Dougherty K,
Dove L,
Everhart J,
Ferris M,
Fried MW,
Geahigan T,
Gibson K,
Haritos M,
Harsh D,
Heberlein J,
Hermitt C,
Hinds M,
Howell C,
Howell CD,
Im K,
Im K,
Jeffers LJ,
Kelley S,
Kelsey S,
Klarquist J,
Koozer L,
Lawlor S,
Lewis J,
Liang TJ,
Liang TJ,
Martin M,
Ramcharran D,
Rhodes SL,
Robuck P,
Rosen HR,
Rosen HR,
Sanda C,
Shrestha R,
Smith SR,
Stovel S,
Straley S,
Su X,
Tang G,
Tang Y,
Tavis JE,
Taylor MW,
Taylor MW,
Theodore D,
Thomas SB,
Tong X,
Tsukahara T,
Virahep-C Study Group,
Wahed A,
Wang P,
Wei Y,
Weston S,
Wiley TE,
Williams M,
Yang H,
Yang H,
Yao E,
Yee LJ,
Yee LJ,
Zhang S
Studies:
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C
Interferon signaling pathway genes (IPGs) and interferon-stimulated genes (ISGs) are associated with the host response to hepatitis C virus (HCV) infection. We studied single nucleotide polymorphisms (SNPs) in IPGs and ISGs for their associations with response to pegylated interferon alpha-2a (Peg-IFN-alpha) plus ribavirin therapy in HCV genotype-1 infected patients.